AstraZeneca considers potential 400 billion dollar merger with Bristol Myers Squibb

Shares of AstraZeneca fell by more than six percent on Monday following reports that the British pharmaceutical giant has explored a potential mega-merger with American rival Bristol Myers Squibb. Insider reports suggest the proposed transaction could create a combined corporate entity valued at roughly $400 billion.

If pursued, the consolidation would rank among the largest corporate mergers in the pharmaceutical sector's history, potentially reshaping global markets for oncology and immunology therapies. However, industry observers and legal experts emphasize that a deal of this magnitude would face significant regulatory scrutiny and complex antitrust hurdles from competition authorities in both Europe and the United States. Neither company has officially confirmed that formal negotiations are taking place.

Sources: FAZ.